WuXi Biologics (Cayman) Inc. Share Price
Equities
2269
KYG970081173
Biotechnology & Medical Research
OTC Markets Traded|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.02 HKD | +0.06% |
|
-2.48% | +5.03% |
| Capitalization | 119B 137B 17.43B 15.03B 13.77B 13.01B 23.99B 1,688B 24.6B 164B 63.92B 794B 65.41B 64.02B 2,774B | P/E ratio 2026 * |
21.7x | P/E ratio 2027 * | 18.1x |
|---|---|---|---|---|---|
| Enterprise value | 108B 124B 15.86B 13.68B 12.53B 11.84B 21.83B 1,536B 22.38B 149B 58.16B 723B 59.52B 58.25B 2,524B | EV / Sales 2026 * |
4.28x | EV / Sales 2027 * | 3.57x |
| Free-Float |
90.02% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: WuXi Biologics (Cayman) Inc.
| 1 day | +0.06% | ||
| 1 week | -2.48% | ||
| Current month | -0.06% | ||
| 1 month | -7.20% | ||
| 3 months | -18.06% | ||
| 6 months | +2.55% | ||
| Current year | +5.03% |
| 1 week | 32.3 |  | 34.7 |
| 1 month | 32.02 | | 35.82 |
| Current year | 30.94 | | 44 |
| 1 year | 22.95 | | 44 |
| 3 years | 10.14 | | 52.45 |
| 5 years | 10.14 | | 148 |
| 10 years | 8.33 | | 148 |
| Manager | Title | Age | Since |
|---|---|---|---|
Zhi Sheng Chen
CEO | Chief Executive Officer | 54 | 31/12/2015 |
Ming Tu
DFI | Director of Finance/CFO | 56 | 22/08/2021 |
Xuejun Gu
CTO | Chief Tech/Sci/R&D Officer | 55 | 30/03/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Ge Li
CHM | Chairman | 59 | 31/01/2014 |
Zhi Sheng Chen
BRD | Director/Board Member | 54 | 31/01/2014 |
Yan Ling Cao
BRD | Director/Board Member | 42 | 30/04/2016 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.06% | -2.48% | +36.73% | -25.88% | 17.43B | |
| +1.39% | -1.89% | +35.11% | +77.37% | 49.39B | |
| -0.25% | -7.74% | +66.73% | +51.47% | 45.18B | |
| +0.24% | -7.41% | +58.24% | +451.95% | 23.28B | |
| -1.19% | -6.27% | -10.24% | -17.56% | 22.2B | |
| -1.98% | -3.24% | +25.53% | -41.28% | 15.79B | |
| +0.18% | -11.23% | +37.14% | +198.55% | 13.26B | |
| +0.84% | -4.24% | +28.93% | - | 12.79B | |
| -2.35% | -1.60% | +8.91% | +145.93% | 12.23B | |
| -1.06% | -16.36% | -33.99% | +843.45% | 12.3B | |
| Average | -0.41% | -6.54% | +25.31% | +187.11% | 22.39B | |
| Weighted average by Cap. | -0.10% | -5.68% | +33.39% | +142.00% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 25.22B 29.01B 3.7B 3.19B 2.93B 2.76B 5.1B 358B 5.22B 34.86B 13.58B 169B 13.89B 13.6B 589B | 29.43B 33.85B 4.32B 3.73B 3.41B 3.23B 5.95B 418B 6.1B 40.69B 15.85B 197B 16.22B 15.87B 688B |
| Net income | 5.49B 6.31B 806M 695M 637M 602M 1.11B 78.04B 1.14B 7.59B 2.96B 36.74B 3.02B 2.96B 128B | 6.64B 7.64B 975M 841M 770M 728M 1.34B 94.4B 1.38B 9.18B 3.58B 44.44B 3.66B 3.58B 155B |
| Net Debt | -10.69B -12.3B -1.57B -1.35B -1.24B -1.17B -2.16B -152B -2.22B -14.78B -5.76B -71.55B -5.89B -5.77B -250B | -13.68B -15.73B -2.01B -1.73B -1.59B -1.5B -2.76B -194B -2.83B -18.91B -7.36B -91.54B -7.54B -7.38B -320B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/05/26 | 33.02 $ | +0.06% | 11,154,226 |
| 19/05/26 | 33.00 $ | +0.18% | 17,366,800 |
| 18/05/26 | 32.94 $ | -2.20% | 39,572,030 |
| 15/05/26 | 33.68 $ | +3.19% | 35,563,540 |
| 14/05/26 | 32.64 $ | -3.60% | 26,986,420 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 2269 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition